Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study
Latest Information Update: 09 Apr 2022
At a glance
- Drugs Baricitinib (Primary) ; Lopinavir/ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms BARI-COVID
- 19 Apr 2020 Planned number of patients changed from 60 to 200.
- 19 Apr 2020 Planned End Date changed from 30 Apr 2020 to 30 Jul 2020.
- 19 Apr 2020 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.
Most Recent Events
Trial Overview
Purpose
There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. Since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.The evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.
Primary Endpoints
The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.
description: The percentage of ICU admission in patients and controls will be compared for statistical difference
time_frame: 2 weeks
Other Endpoints
The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.
description: CRP values will be evaluated for prediction of disease worsening.
time_frame: 2 weeks [1]
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Biomarker
| NCT Number | Biomarker Name | Biomarker Function |
|---|---|---|
| NCT04320277 | C-reactive protein (CRP) | Detailed Description, Outcome Measure |
| Interleukin-6 (IL-6) | Detailed Description, Outcome Measure | |
| Tumor necrosis factor alpha (TNF-alpha) | Detailed Description, Outcome Measure |
Subjects
- Subject Type patients
-
Number
Planned: 200
- Sex male & female
- Age Group 18-85 years; adult; elderly
Patient Inclusion Criteria
- All consecutive patients with mild to moderate COVID-19 infection - Age >18 years, - Clinical diagnosis of COVID19 infection - Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia. - All patients should be willing and able to provide written informed consent prior to performing study procedures.
Patient Exclusion Criteria
- Age less than 18 - History of thrombophlebitis. - Patient with latent tuberculosis infection (Quantiferon test). - Pregnancy and lactation.
Trial Details
Identifiers
| Identifier | Owner |
|---|---|
| NCT04320277 | ClinicalTrials.gov: US National Institutes of Health |
| HPrato3 | - |
Trial Dates
-
Initiation Dates
Planned : 16 May 2020
Actual : 16 May 2020
-
Primary Completion Dates
Planned : 30 Jun 2020
-
End Dates
Planned : 30 Jul 2020
Other Details
- Design crossover; open; prospective
- Phase of Trial Phase II/III
- Location Italy
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| BaricitinibPrimary Drug | Oral | Tablet |
| Lopinavir/ritonavirPrimary Drug | Oral | Tablet |
Controls
All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine. Drug: Baricitinib (Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.) Other Name: Lopinavir/Ritonavir tablets 250 mg/bid
Patients
All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks. Drug: Baricitinib (Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.) Other Name: Lopinavir/Ritonavir tablets 250 mg/bid
Trial Centres
Investigators
| Investigator | Centre Name | Trial Centre Country |
|---|---|---|
|
Fabrizio Cantini
+39 3408075607
show details
fbrzcantini@gmail.com |
Fabrizio Cantini | Italy |
|
Fabrizio Cantini, MD
+393408075607
show details
fbrzcantini@gmail.com |
Hospital of Prato, Italy |
-
|
|
Laura Niccoli, MD
+39 3339849690
show details
lniccoli64@gmail.com |
-
|
Centres
| Centre Name | Location | Trial Centre Country |
|---|---|---|
| - |
-
|
-
|
| Fabrizio Cantini | Prato, Tuscany | Italy |
| Hospital of Prato |
-
|
-
|
| Hospital of Prato, Italy |
-
|
-
|
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 09 Apr 2022 | Other trial event | According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2020). Updated 09 Apr 2022 |
| 09 Apr 2022 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 09 Apr 2022 |
| 22 Apr 2020 | Biomarker Update | Biomarkers information updated Updated 04 Nov 2021 |
| 19 Apr 2020 | Other trial event | Planned number of patients changed from 60 to 200. Updated 23 Apr 2020 |
| 19 Apr 2020 | Completion date | Planned End Date changed from 30 Apr 2020 to 30 Jul 2020. Updated 23 Apr 2020 |
| 19 Apr 2020 | Other trial event | Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020. Updated 23 Apr 2020 |
| 19 Apr 2020 | Other trial event | Planned initiation date changed from 16 Mar 2020 to 16 May 2020. Updated 23 Apr 2020 |
| 19 Apr 2020 | Status change - not yet recruiting | Status changed from recruiting to not yet recruiting. Updated 23 Apr 2020 |
| 27 Mar 2020 | New trial record | New trial record Updated 27 Mar 2020 |
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG